Phase III on the TEMSO analyze observed that teriflunomide substantially slowed brain volume reduction when compared with placebo above two yrs in clients with relapsing MS. Data acquired from MRI were utilized to assess people dealt with with fourteen mg or seven mg of the drug, or placebo. Most individuals http://andersonz456ppo7.blogs100.com/profile